PD 115934
Alternative Names: NSC 366140; Pyrazoloacridine; PZALatest Information Update: 25 Sep 2021
At a glance
- Originator Pfizer
- Developer National Institutes of Health (USA); Pfizer
- Class Acridines; Pyrazoles; Small molecules
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Renal cancer
Most Recent Events
- 25 Sep 2006 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 25 Sep 2006 Discontinued - Phase-II for Colorectal cancer in USA (IV-infusion)
- 25 Sep 2006 Discontinued - Phase-II for Endometrial cancer in USA (IV-infusion)